Caribou Biosciences (CRBU) Amortizatization of Intangibles (2021 - 2026)
Caribou Biosciences (CRBU) reported Amortizatization of Intangibles of $269000.0 for Q1 2026, down 40.49% year-over-year from $452000.0 in Q1 2025, and up 68.12% quarter-over-quarter from $160000.0 in Q4 2025.
Caribou Biosciences (CRBU) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 6 years of Amortizatization of Intangibles data on file, last reported at $269000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $269000.0, down 40.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $957000.0 (down 73.7% YoY), and the FY2025 annual result was $1.1 million, down 75.88% from the prior year.
- Amortizatization of Intangibles climbed to $269000.0 in Q1 2026 per CRBU's latest filing, from $160000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.4 million in Q3 2023 and troughed at -$1.6 million in Q4 2023.
- A 5-year average of $668058.8 and a median of $452000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles surged 1836.54% in 2022, then slumped 279.07% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $903000.0 in 2022, then tumbled by 279.07% to -$1.6 million in 2023, then soared by 162.96% to $1.0 million in 2024, then plunged by 84.28% to $160000.0 in 2025, then jumped by 68.12% to $269000.0 in 2026.
- Business Quant data shows CRBU's Amortizatization of Intangibles at $269000.0 in Q1 2026, $160000.0 in Q4 2025, and $235000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | 269,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 269,000.00 |
| Mar 31, 2026 | 269,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Sep 30, 2025 | 235,000.00 |
| Sep 30, 2025 | 235,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 946,000.00 |
| Jun 30, 2024 | 946,000.00 |
| Mar 31, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Dec 31, 2023 | -1.62 Mn |